Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines

Lung Cancer

Volumn 38, Issue 1, 2002, Pages 43-50

  Kawamura Akiyama, Yoshiko ^a,c   Kusaba, Hitoshi ^a   Kanzawa, Fumihiko ^a   Tamura, Tomohide ^b   Saijo, Nagahiro ^b   Nishio, Kazuto ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cisplatin; Cisplatin resistance; Lung cancer; ZD0473

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; CISPLATIN; GLUTATHIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL LINE; CONTROLLED STUDY; CROSS RESISTANCE; DOSE CALCULATION; DRUG ACCUMULATION; DRUG EFFECT; DRUG POTENCY; DRUG TOLERANCE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0036806705     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00175-7     Document Type: Article

References (38)

1. Harrap K.R. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 12:(Suppl A):1985;21-33.
2. Kelland L.R., Abel G., McKeage M.J., et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res. 53:1993;2581-2586.
3. Kelland L.R., Barnard C.F., Mellish K.J., et al. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res. 54:1994;5618-5622.
4. Pendyala L., Creaven P.J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 53:1993;5970-5976.
5. Perez R.P. Cellular and molecular determinations of cisplatin resistance. Eur. J. Cancer. 34:1998;1535-1542.
6. Nishio K., Nakamura T., Koh Y., Suzuki T., Fukumoto H., Saijo N. Drug resistance in lung cancer. Curr. Opin. Oncol. 11:1999;109-115.
7. Andrews P.A., Velury S., Mann S.C., Howell S.B. cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 48:1988;68-73.
8. Bungo M., Fujiwara Y., Kasahara K., et al. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum (II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res. 50:1990;2549-2553.
9. Andrews P.A., Howell S.B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 2:1990;35-43.
10. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 269:1994;787-790.
11. Kelley S.L., Basu A., Teicher B.A., Hacker M.P., Hamer D.H., Lazo J.S. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 241:1988;1813-1815.
12. Kasahara K., Fujiwara Y., Nishio K., et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res. 51:1991;3237-3242.
13. Roberts J.J., Kotsaki-Kovatsi V.P. Potentiation of sulphur mustard or cisplatin-induced toxicity by caffeine in Chinese hamster cells correlates with formation of DNA double strand breaks during replication on a damaged template. Mutat. Res. 165:1986;207-220.
14. Eastman A., Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry. 27:1988;4730-4734.
15. Hromas R.A., Andrews P.A., Murphy M.P., Burns C.P. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett. 34:1987;9-13.
16. Mann S.C., Andrews P.A., Howell S.B. Modulation of cis-diamminedichloroplatinum (II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int. J. Cancer. 48:1991;866-872.
17. Morikage T., Bungo M., Inomata M., et al. Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn. J. Cancer Res. 82:1991;747-751.
18. Holford J., Sharp S.Y., Murrer B.A., Abrams M., Kelland L.R. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br. J. Cancer. 77:1998;366-373.
19. Kelland L.R. AMD473. Drugs Fut. 23:1998;1062-1065.
20. Holford J., Raynaud F., Murrer B.A., et al. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anticancer Drug Des. 13:1998;1-18.
21. Raynaud F.I., Boxall F.E., Goddard P.M., et al. cis-Amminedichloro (2-methylpyridine) platinum (II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin. Cancer Res. 3:1997;2063-2074.
22. Hong W.S., Saijo N., Sasaki Y., et al. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int. J. Cancer. 41:1988;462-467.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application of proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
24. Ohmori T., Morikage T., Sugimoto Y., et al. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin resistant subline (PC-14/CDDP). Jpn. J. Cancer Res. 84:1993;83-92.
25. Kurokawa H., Ishida T., Nishio K., et al. Gamma-glutamylcysteine synthetase gene overexpression results in increase activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem. Biophys. Res. Commun. 216:1995;258-264.
26. Meijer C., Mulder N.H., Hospers G.A., Uges D.R., de Vries E.G. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br. J. Cancer. 62:1990;72-77.
27. United Kingdom Co-Ordinating Committee on Cancer Research. Guidelines for the welfare of animals in experimental neoplasia (2nd ed). Br. J. Cancer. 77:1998;1-10.
28. Kelland L.R., Sharp S.Y., O'Neill C.F., Raynaud F.I., Beale P.J., Judson I.R. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. J. Inorg. Biochem. 77:1999;111-115.
29. Kelland L.R. Meeting report on 8th international symposium on platinum and other metal coordination compounds in cancer chemotherapy. J. Inorg. Biochem. 77:1999;121-124.
30. Hoctin-Boes G., Cosaert J., Koehler M., Smith M. Safety profile of ZD0473 in phase II trials of patients with advanced cancers. Proc. Am. Soc. Clin. Oncol. 20:2001;344a. (abstract 1372).
31. Vandenberg T.A., Gelmon K., Panasci L., et al. A Phase II trial of ZD0473 in patients with metastatic breast cancer a National Cancer Institute of Canada - Clinical Trials Group Study (NCIC CTG-IND 129). Proc. Am. Soc. Clin. Oncol. 20:2001;58b. (abstract 1981).
32. Morikage T., Ohmori T., Nishio K., Fujiwara Y., Takeda Y., Saijo N. Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res. 53:1993;3302-3307.
33. Ohmori T., Nishio K., Ohta S., et al. Ouabain-resistant non-small-cell lung-cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum(II)(CDDP). Int. J. Cancer. 57:1994;111-116.
34. Kurokawa H., Nishio K., Ishida T., et al. Effect of glutathione depletion on cisplatin resistance in cancer cells transfected with the γ-glutamylcysteine synthetase gene. Jpn. J. Cancer Res. 88:1997;108-110.
35. Ishikawa T., Wright C.D., Ishizuka H. GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J. Biol. Chem. 269:1994;29085-29093.
36. Ishida T., Nishio K., Kurokawa H., et al. Circumvention of glutathione-mediated mitomycin C resistance by a novel mitomycin C analogue, KW-2149. Int. J. Cancer. 72:1997;865-870.
37. Singh S.V., Xu B.H., Maurya A.K., Mian A.M. Modulation of mitomycin C resistance by glutathione transferase inhibitor ethacrynic acid. Biochim. Biophys. Acta. 1137:1992;257-263.
38. Xu B.H., Singh S.V. Potentiation of mitomycin C cytotoxicity by glutathione depletion in a multidrug resistant mouse leukemia cell line. Cancer Lett. 66:1992;49-53.